PRLD (Prelude Therapeutics) Insider Ownership: 4.30 % (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRLD Prelude Therapeutics Inc PRLD
22 GF Score
Price $4.18
! 3 Warning Signs
View Full Analysis

What is Prelude Therapeutics Insider Ownership?

Prelude Therapeutics PRLD -6.28% 22 Insider Ownership is 4.30 % as of Jul. 17, 2026. GuruFocus rates PRLD with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Prelude Therapeutics's insider ownership is 4.30%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Prelude Therapeutics's Institutional Ownership is 47.54%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Prelude Therapeutics's Float Percentage Of Total Shares Outstanding is 31.58%.

Prelude Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Prelude Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prelude Therapeutics Insider Ownership Chart

Prelude Therapeutics Historical Data

The historical data trend for Prelude Therapeutics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 5.86 5.88 5.86 5.86 5.87 5.29 5.29 5.29 4.30 4.30
PRLD
22GF Score
Prelude Therapeutics Inc PRLD
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 4.30 % mean?
Prelude Therapeutics (PRLD) has a Insider Ownership of 4.30 % as of Jul. 17, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Prelude Therapeutics and its competitors.
Is Prelude Therapeutics' Insider Ownership too high?
Prelude Therapeutics' current Insider Ownership is 4.30 %. Overall, Prelude Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Insider Ownership compare to DMAC and RCKT?
Prelude Therapeutics' Insider Ownership of 4.30 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Prelude Therapeutics and its competitors. Prelude Therapeutics's current Insider Ownership is 4.30 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Insider Ownership of 4.30 %. The current Insider Ownership is 4.30 %. Prelude Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Insider Ownership is 4.30 % as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
22GF Score

Get the complete analysis for PRLD

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.18
Price